Product Datasheet
www.leinco.com
excellence in early discovery research       




Rabbit Anti-Anthrax Anthrax Lethal Factor (Anthrax LF)
Purified No Carrier Protein
Polyclonal Antibody
Share |


Prod. No.:A284
Host:Rabbit
Conc.:0.5 mg/ml
Pkg. Size:0.1 mg, 0.5 mg, 1 mg
Storage:2-8°C Detailed storage instructions below.
Description
Specificity:
Rabbit Anti-Anthrax Lethal Factor (Anthrax LF) recognizes an epitope in the intermediate domain of Anthrax LF. This polyclonal antibody was purified using affinity chromatography.

Background:
Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF) (1,2 for review). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR)3 and capillary morphogenesis protein 2 (CMG2),4 although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. LF is the primary toxin of anthrax and functions as a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near their amino terminus, interfering with MAPK signaling and inducing apoptosis.

Known Species Cross Reactivity: Bacteria
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Stability
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Reported Applications
Indirect ELISA
Each investigator should determine their own optimal working dilution for specific applications.


Country of Origin
USA
References
1. Schwartz, M. N. (2001) New Engl. J. Med. 345:1621
2. Moayeri, M. et al. (2004) Curr. Opin. Microbiol. 7:19
3. Bradley, K. A. et al. (2001) Nature 414:225
4. Scobie, H. M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:5170
Related Products
Anti-Anthrax Lethal Factor (CT) (Leinco Prod. No.: A283)
Anthrax LF (CT) Blocking Peptide (Leinco Prod. No.: A304)
Anthrax LF (Intermediate Domain) Blocking Peptide (Leinco Prod. No.: A305)
800.538.1145 ® Copyright Leinco Technologies, Inc. 2006 – 2013